Samantha Sze-Yee Lee

Samantha Sze-Yee Lee

Auto-generated profile, based on publicly available information

Samantha Sze-Yee Lee

Centre for Ophthalmology and Visual Science (incorporating Lions Eye Institute), University of Western Australia, Perth, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2022 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
SLSamantha Sze-Yee Lee
Samantha Sze-Yee Lee
GLGareth Lingham
Gareth Lingham
PSPaul G. Sanfilippo
Paul G. Sanfilippo
CHChristopher J. Hammond
Christopher J. Hammond
SSSeang-Mei Saw
Seang-Mei Saw
DMDavid A. Mackey
David A. Mackey
The global myopia epidemic is well reported1,2 and the rate of myopia-associated complications is expected to similarly rise as younger generations with high myopia prevalence approach middle age and older age.3,4 Myopia typically develops and progresses fastest during childhood, and it has been reported that myopia stabilizes (defined as change of less than 0.5 diopters [D]) at around age 15 to 16 years.5,6 However, longitudinal studies involving university students have demonstrated that myopia may progress and even start to develop during young adulthood. In 118 university students who were observed for 3 years in Portugal7 (mean age, 21 years at baseline), prevalence of myopia and hyperopia increased by 5% and decreased by 9%, respectively, while mean spherical equivalent decreased by 0.3 D. Another study in Norway8 found a 3-year myopia incidence of 33% among university students (mean age, 21 years at baseline), with mean spherical equivalent decreasing by 0.6 D. Similar longitudinal findings were reported in university students in Denmark9 and the US.10,11

9 September 2022 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Open access
SLSamantha Sze‐Yee Lee
Samantha Sze‐Yee Lee
GLGareth Lingham
Gareth Lingham
MBMagdalena Blaszkowska
Magdalena Blaszkowska
PSPaul G. Sanfilippo
Paul G. Sanfilippo
AKAdrian Koay
Adrian Koay
DMDavid A. Mackey
David A. Mackey
Background: To test the hypothesis that 0.01% atropine eyedrops are a safe and effective myopia‐control approach in Australian children.Methods: Children (6–16 years; 49% Europeans, 18% East Asian, 22% South Asian, and 12% other/mixed ancestry) with documented myopia progression were enrolled into this single‐centre randomised, parallel, double‐masked, placebo‐controlled trial and randomised to receive 0.01% atropine (n = 104) or placebo (n = 49) eyedrops (2:1 ratio) instilled nightly over 24 months (mean index age = 12.2 ± 2.5 and 11.2 ± 2.8 years, respectively). Outcome measures were the changes in spherical equivalent (SE) and axial length (AL) from baseline.Results: At 12 months, the mean SE and AL change from baseline were −0.31D (95% confidence interval [CI] = −0.39 to −0.22) and 0.16 mm (95%CI = 0.13–0.20) in the atropine group and −0.53D (95%CI = −0.66 to −0.40) and 0.25 mm (95%CI = 0.20–0.30) in the placebo group (group difference p ≤ 0.01). At 24 months, the mean SE and AL change from baseline was −0.64D (95%CI = −0.73 to −0.56) and 0.34 mm (95%CI = 0.30–0.37) in the atropine group, and −0.78D (95%CI = −0.91 to −0.65) and 0.38 mm (95%CI = 0.33–0.43) in the placebo group. Group difference at 24 months was not statistically significant (p = 0.10). At 24 months, the atropine group had reduced accommodative amplitude and pupillary light response compared to the placebo group.Conclusions: In Australian children, 0.01% atropine eyedrops were safe, well‐tolerated, and had a modest myopia‐control effect, although there was an apparent decrease in efficacy between 18 and 24 months, which is likely driven by a higher dropout rate in the placebo group.

11 September 2023 in Acta Ophthalmologica
Verified
Journal Article
Open access
JLJames Loughman
James Loughman
EKEmmanuel Kobia‐Acquah
Emmanuel Kobia‐Acquah
GLGareth Lingham
Gareth Lingham
JBJohn Butler
John Butler
ELEkaterina Loskutova
Ekaterina Loskutova
DFDaniel Ian Flitcroft
Daniel Ian Flitcroft
Purpose: The Myopia Outcome Study of Atropine in Children (MOSAIC) is an investigator‐led, double‐masked, randomized controlled trial investigating the efficacy and safety of 0.01% atropine eye drops for managing myopia progression in a predominantly White, European population.Methods: Children aged 6–16 years with myopia were randomly allocated 2:1 to nightly 0.01% atropine or placebo eye drops in both eyes for 2 years. The primary outcome was cycloplegic spherical equivalent (SE) progression at 24 months. Secondary outcomes included axial length (AL) change, safety and acceptability. Linear mixed models with random intercepts were used for statistical analyses.Results: Of 250 participants enrolled, 204 (81.6%) completed the 24‐month visit (136 (81.4%) treatment, 68 (81.9%) placebo). Baseline characteristics, drop‐out and adverse event rates were similar between treatment and control groups. At 24 months, SE change was not significantly different between 0.01% atropine and placebo groups (effect = 0.10 D, p = 0.07), but AL growth was lower in the 0.01% atropine group, compared to the placebo group (−0.07 mm, p = 0.007). Significant treatment effects on SE (0.14 D, p = 0.049) and AL (−0.11 mm, p = 0.002) were observed in children of White, but not non‐White (SE = 0.05 D, p = 0.89; AL = 0.008 mm, p = 0.93), ethnicity at 24 months. A larger treatment effect was observed in subjects least affected by COVID‐19 restrictions (SE difference = 0.37 D, p = 0.005; AL difference = −0.17 mm, p = 0.001).Conclusions: Atropine 0.01% was safe, well‐tolerated and effective in slowing axial elongation in this European population. Treatment efficacy varied by ethnicity and eye colour, and potentially by degree of COVID‐19 public health restriction exposure during trial participation.

27 April 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
SLSamantha Sze-Yee Lee
Samantha Sze-Yee Lee
DMDavid A. Mackey
David A. Mackey
Myopia tends to develop and progress fastest during childhood, and the age of stabilization has been reported to be 15–16 years old. Thus, most studies on myopia have centered on children. Data on the refractive error profile in young adulthood — a time in life when myopia is thought to have stabilized and refractive error is unaffected by age-related pathology such as cataract — are limited. The Raine Study has been following a community-based cohort of young adults representative of the general Western Australia population since their prenatal periods in 1989–1991, with eye examinations performed when participants were 20 and 28 years old. At 20 years old, prevalence of myopia in the cohort was 25.8%. Using long-term trajectory of serum vitamin D levels and conjunctival ultraviolet autofluorescence (CUVAF) area to objectively quantify sun exposure, the Raine Study confirmed a negative relationship between time spent outdoors and myopia prevalence. However, prospective studies are required to determine the amount of CUVAF area or serum vitamin D levels associated with time duration. Combining data from the Raine Study and several other cohorts, Mendelian randomization studies have confirmed a link between myopia and a genetic predisposition toward higher education. Several novel potential associations of myopia or ocular biometry were investigated, including fetal growth trajectory, which was found to be significantly associated with corneal curvature at 20 years. By age 28, myopia prevalence had increased to 33.2%. Between 20 and 28 years old, myopia progressed and axial length elongated, on average, by −0.041D/year and 0.02 mm/year, respectively. Smaller CUVAF area at follow-up, female sex, and parental myopia were significant risk factors for myopia incidence and progression between 20 and 28 years. Given the limited research in young adults, further investigations are warranted to confirm the Raine Study findings, as well as identify novel genetic or environmental factors of myopia incidence and progression in this age group.

25 October 2019 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
AAAugusto Azuara-Blanco
Augusto Azuara-Blanco
NLNicola Logan
Nicola Logan
NSNiall Strang
Niall Strang
KSKathryn Saunders
Kathryn Saunders
PAPeter M Allen
Peter M Allen
MCMike Clarke
Mike Clarke
Background/aims To report the protocol of a trial designed to evaluate the efficacy, safety and mechanism of action of low-dose atropine (0.01%) eye-drops for reducing progression of myopia in UK children. Methods Multicentre, double-masked, superiority, placebo-controlled, randomised trial. We will enrol children aged 6–12 years with myopia of −0.50 dioptres or worse in both eyes. We will recruit 289 participants with an allocation ratio of 2:1 (193 atropine; 96 placebo) from five centres. Participants will instil one drop in each eye every day for 2 years and attend a research centre every 6 months. The vehicle and preservative will be the same in both study arms. The primary outcome is SER of both eyes measured by autorefractor under cycloplegia at 2 years (adjusted for baseline). Secondary outcomes include axial length, best corrected distance visual acuity, near visual acuity, reading speed, pupil diameter, accommodation, adverse event rates and allergic reactions, quality of life (EQ-5D-Y) and tolerability at 2 years. Mechanistic evaluations will include: peripheral axial length, peripheral retinal defocus, anterior chamber depth, iris colour, height and weight, activities questionnaire, ciliary body biometry and chorioretinal thickness. Endpoints from both eyes will be pooled in combined analysis using generalised estimating equations to allow for the correlation between eyes within participant. Three years after cessation of treatment, we will also evaluate refractive error and adverse events. Conclusions The Childhood Atropine for Myopia Progression in the UK study will be the first randomised trial reporting outcomes of low-dose atropine eye-drops for children with myopia in a UK population. Trial registration number ISRCTN99883695, NCT03690089.

16 March 2022 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Open access
SLSamantha S. Y. Lee
Samantha S. Y. Lee
VNVinay K. Nilagiri
Vinay K. Nilagiri
DMDavid A. Mackey
David A. Mackey
There is a growing body of literature on the effects of sleep disorders, in particular obstructive sleep apnoea (OSA), on ocular health, with consistent evidence of an increased risk of floppy eyelid syndrome, non‐arteritic anterior ischaemic optic neuropathy, diabetic macular oedema, and other retinal vasculature changes in individuals with OSA. However, reports on OSA's associations with glaucoma, papilloedema, diabetic retinopathy, central serous chorioretinopathy, and keratoconus have been conflicting, while links between OSA and age‐related macular degeneration have only been described fairly recently. Despite numerous suggestions that OSA treatment may reduce risk of these eye diseases, well‐designed studies to support these claims are lacking. In particular, the ocular hypertensive effects of continuous positive airway pressure (CPAP) therapy for OSA requires further investigation into its potential impact on glaucoma risk and management. Reports of ocular surface complications secondary to leaking CPAP masks highlights the importance of ensuring good mask fit. Poor sleep habits have also been linked with increased myopia risk; however, the evidence on this association remains weak.